Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Middle East Regulatory Affairs Director Adel Djalal On Drug Pricing And Regulatory Environment - An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

Amgen is targeting the Middle East as a new growth area, and it plans to venture further into Gulf countries, from Saudi Arabia and war-torn Iraq to countries like Algeria and Libya.
Advertisement

Related Content

Quintiles Continues Eastward Push, Looks To Russia And Middle East For Growth
Saudi FDA Licensing Director Hajed Hashan On CTD And Drug Licensing: An Interview With PharmAsia News
Saudi FDA Licensing Director Hajed Hashan On CTD And Drug Licensing: An Interview With PharmAsia News
Amgen Middle East Regulatory Director On Regulatory Expertise And Drug Pricing - An Interview With PharmAsia News (Part 1 of 2)
Amgen Middle East Regulatory Director On Regulatory Expertise And Drug Pricing - An Interview With PharmAsia News (Part 1 of 2)
Dubiotech Bets On ''If You Build It, They Will Come,'' Despite Funding Shortages
Advertisement
UsernamePublicRestriction

Register

SC077277

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel